Skip to content
Axcess News – Lifestyle
Author:
FibroBiologics, Inc.
FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
September 29, 2026
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
September 17, 2026
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing
September 3, 2026
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
September 1, 2026
FibroBiologics Appoints Leigh Steinberg to Board of Directors
August 24, 2026
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease
August 20, 2026
FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints
August 18, 2026
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets
August 11, 2026
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage
August 5, 2026
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
July 31, 2026
1
2
3
Next Page
→